Market Cap (In AUD)
23.74 Million
Revenue (In AUD)
1.69 Million
Net Income (In AUD)
-6.85 Million
Avg. Volume
94.29 Thousand
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.042-0.185
- PE
- -
- EPS
- -
- Beta Value
- 2.415
- ISIN
- AU000000RHY2
- CUSIP
- Q8137L104
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Dr. David Atkins M.B.A., Ph.D.
- Employee Count
- -
- Website
- https://www.rhythmbio.com
- Ipo Date
- 2017-12-06
- Details
- Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
More Stocks
-
PYRAMIDPyramid Technoplast Limited
PYRAMID
-
SMAGSmart Agro - Limited
SMAG
-
GIANLIFEGian Life Care Limited
GIANLIFE
-
XTDTDb Split Corp.
XTD
-
SDISDI Limited
SDI
-
CPS
-
002184
-
GNL